Canada’s advanced therapies face critical access delays

A gene therapy approved to slow vision loss in children went unused for years after Health Canada’s approval. The treatment was available, the science was proven, and regulators had cleared it—but Charmain Brown’s family still faced uncertainty over eligibility, delivery methods, and provincial coverage. This gap between scientific breakthroughs and patient access has become a central issue in Canada’s health care system, one that will grow as advanced therapies transition from research labs to clinical use.

Cell and gene therapies, tissue-engineered treatments, and regenerative medicine offer cures or management for conditions once deemed untreatable. However, the current evaluation system was built for traditional pharmaceuticals, not for therapies where the production process itself is part of the cure. Rare diseases often lack large-scale clinical trials, and some treatments are customized for individual patients. The current approach—where regulation, pricing, and adoption operate in isolation—introduces delays that can close critical treatment windows for infants with rapidly worsening genetic disorders.

Canada has invested billions in biomanufacturing and life sciences, but true health sovereignty requires more than production capacity. It demands a smooth pathway from research to patient care. A recent Stem Cell Network report examined three Canadian-developed therapies: a gene therapy for a fatal newborn disease, a bioengineered skin graft for severe burns, and a personalized treatment for a rare pediatric neurodevelopmental condition. Each case exposed systemic flaws, regulatory bottlenecks, fragmented funding streams, and disconnected health care infrastructure, that block timely access.

Regulatory gaps stall life-saving therapies

The federal Pharmaceutical and Life Sciences Sector Task Force has pushed for modernization, including streamlined regulatory reviews and coordinated support for advanced therapies. While the government considers these recommendations, the emphasis must remain on regenerative medicine. Canada excels in research and clinical expertise, yet the system lacks the agility to keep pace with innovation. Many approved treatments stall in practice, leaving families like Brown’s without options.

Hospitals must prepare staff, facilities, and diagnostics before therapies are adopted. Regulators, assessors, and insurers should collaborate where possible, and funding must cover all treatment-related costs, development, manufacturing, specialized care, and patient travel. A key near-term action would be fully implementing the Advanced Therapeutic Products framework, establishing coordinated pathways from development to long-term evidence collection with provincial and territorial governments.

Establishing a clear route for Canadian innovations is equally vital. Early guidance, coordinated advice, and strategic prioritization, without compromising standards, would prevent promising therapies from failing in a fragmented system. The competition for life sciences talent and investment is fierce. If Canada’s processes remain rigid, its top researchers and manufacturers may relocate to regions with more adaptive regulation and streamlined pathways.

Coordination, not just research, fixes Canada’s delays

Health sovereignty begins with integrating existing strengths, scientific research, regulatory oversight, manufacturing, and clinical care, into a unified system. Canada already possesses many necessary components; the missing element is coordination. For families awaiting treatments, the difference between an approved therapy and one they can access is decisive. The next hurdle isn’t just developing these medicines; it’s ensuring Canadians can use them.

In 2023, Health Canada approved Luxturna, a gene therapy for inherited retinal dystrophy, but provincial coverage remained inconsistent. Families in Ontario and British Columbia secured access through private funding or clinical trials, while others in Alberta and Quebec faced months of uncertainty.

Unlike traditional drugs, gene therapies often require specialized infrastructure, cryogenic storage for cell products, dedicated clinics for administration, and long-term monitoring for adverse effects. Hospitals in Toronto and Vancouver have begun retrofitting facilities, but smaller centers in rural areas lack the resources. The Canadian Blood Services has piloted mobile treatment units for hemophilia patients, but scaling such models requires provincial buy-in and sustained funding. Without national standards, provinces operate in isolation, duplicating costs and missing opportunities to optimize care.

Provincial funding fails advanced therapies

The Pan-Canadian Pharmaceutical Alliance has negotiated lower drug prices for conventional medications, but its framework does not extend to advanced therapies. A 2023 analysis by the Canadian Agency for Drugs and Technologies in Health found that only 12% of approved gene therapies were listed on provincial formularies within two years of approval, compared to 87% for small-molecule drugs.

The Stem Cell Network report also highlighted a gene therapy for spinal muscular atrophy, where Canadian researchers developed a treatment but faced regulatory delays in the U.S. before securing approval. By the time Health Canada cleared it, manufacturing partnerships had shifted to American firms, leaving Canadian patients reliant on imports. Similar patterns emerged with a bioengineered skin product for burn victims: the therapy was ready for use, but no province had designated reimbursement codes or clinical pathways.

The federal government funds research through agencies like the Canadian Institutes of Health Research, while provinces handle delivery, often without coordination. For advanced therapies, this siloed structure means that even after approval, families must handle multiple layers of bureaucracy to access care. In some cases, patients have resorted to crowdfunding or traveling to the U.S. for treatment, as seen with a family in Manitoba who raised $200,000 for a gene therapy not covered by provincial plans.

International comparisons show that countries with centralized health systems, such as the UK’s National Health Service, can accelerate adoption. The UK’s Genomics England program has fast-tracked gene therapies for rare diseases by integrating regulatory, funding, and clinical teams under one framework. Canada’s system, by contrast, treats these as separate functions, leading to gaps. For example, while the UK approved a gene therapy for Duchenne muscular dystrophy in 2020, Canadian patients still await provincial funding decisions three years later.